Capricor Therapeutics (NASDAQ:CAPR) specializes in biotechnology with a strong focus on developing transformative cell and exosome-based therapeutics for treating a variety of disorders, particularly those related to cardiovascular and muscular diseases. The company is dedicated to leveraging its innovative technology to address significant unmet medical needs, with a pipeline that includes candidates aimed at conditions such as Duchenne muscular dystrophy and complications related to COVID-19. Capricor's objective is to improve patient outcomes through pioneering research and the advancement of its therapeutic platforms, demonstrating a commitment to excellence and innovation in the field of biomedicine.